Outcomes of genetic subgroups with VEN-based therapy
| Molecular subgroup . | Response (CR/CRi) . | MRD-negative CR/CRi (MFC) . | OS (median or 2-year) . | References . |
|---|---|---|---|---|
| IDH1 | 66.7% (n = 22/33) | 42% (n = 5/12) | 10.2 mo | Pollyea et al. CCR 2022;18 Pratz et al. AJH 202438 |
| IDH2 | 86% (n = 43/50) | 50% (n = 16/32) | 27.5 mo | Pollyea et al. CCR 2022;18 Pratz et al. AJH 202438 |
| NPM1 | 66.7% (n = 18/27) | 88% (n = 15/17) | 2-year OS: 71.8%64 | DiNardo et al. Blood 2020;11 Pratz et al. AJH 202438 |
| FLT3-ITD | 63.3% (n = 19/30) | 53% (n = 9/17) | 9.9 mo | Konopleva et al. CCR 202212 |
| FLT3-TKD | 76.9% (n = 10/13) | 50% (n = 2/4) | 19.2 mo | Konopleva et al. CCR 202212 |
| N/KRAS | 45% (n = 13/29) | - | 12 mo | Rivera et al. AJH 202251 |
| TP53 | 55% (n = 21/38) | 30% (n = 6/20) | 5.5-7.4 mo | DiNardo et al. Blood 2020;11 Pollyea et al. CCR 202213 |
| Molecular subgroup . | Response (CR/CRi) . | MRD-negative CR/CRi (MFC) . | OS (median or 2-year) . | References . |
|---|---|---|---|---|
| IDH1 | 66.7% (n = 22/33) | 42% (n = 5/12) | 10.2 mo | Pollyea et al. CCR 2022;18 Pratz et al. AJH 202438 |
| IDH2 | 86% (n = 43/50) | 50% (n = 16/32) | 27.5 mo | Pollyea et al. CCR 2022;18 Pratz et al. AJH 202438 |
| NPM1 | 66.7% (n = 18/27) | 88% (n = 15/17) | 2-year OS: 71.8%64 | DiNardo et al. Blood 2020;11 Pratz et al. AJH 202438 |
| FLT3-ITD | 63.3% (n = 19/30) | 53% (n = 9/17) | 9.9 mo | Konopleva et al. CCR 202212 |
| FLT3-TKD | 76.9% (n = 10/13) | 50% (n = 2/4) | 19.2 mo | Konopleva et al. CCR 202212 |
| N/KRAS | 45% (n = 13/29) | - | 12 mo | Rivera et al. AJH 202251 |
| TP53 | 55% (n = 21/38) | 30% (n = 6/20) | 5.5-7.4 mo | DiNardo et al. Blood 2020;11 Pollyea et al. CCR 202213 |